ArticleScientific reports2025
Trend analysis of antidepressant consumption in Italy from 2008 to 2022 in a public health perspective.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Antidepressant drug use in Europe: past consumption, prescribing patterns and forecast until 2030.International journal of clinical pharmacy · 2026Article
- Patterns of psychotropic drug dispensation in Portugal amidst the COVID-19 pandemic and beyond.Scientific reports · 2026Article
- Trends in Antidepressant, Anxiolytic, and Cannabinoid Use Among Italian Elite Athletes (2011-2023): A Longitudinal Anti-Doping Analysis.Sports (Basel, Switzerland) · 2025Article
- Antidepressant use in the Canary Islands (Spain): a retrospective study of provincial, island and municipal trends and associated factors.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is an important public health issue. Over the years, the consumption of antidepressants has increased in the population, which on one hand may mean increased diagnostic accuracy, but on the other could mean a problem of inappropriate consumption and prescribing. The aim of the study is to analyze trends in antidepressant consumption and major drug classes in Italy in the last 15 years to provide useful public health insights for policymakers. Data were collected from Osservasalute and OsMed reports from 2008 to 2022. We included the overall consumption of antidepressants and the three subclasses of the most widely used antidepressant drugs: selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs). Data were expressed as the daily defined dose (DDD) per 1,000 inhabitants. A joinpoint analysis was conducted for each data point in order to describe the trend and identify the Annual Percentage Change (APC) and the Average Annual Percent Change (AAPC). In Italy, there was an increase in antidepressant consumption of 36.7% over the period. Overall, Joinpoint analysis shows a significant AAPC of + 2.31%. Analyzing the subclasses also showed a significant increase in the consumption of SSRIs (AAPC = 1.46%) and SNRIs (AAPC = + 2.14%). In contrast, there was a significant decrease in the consumption of TCAs (AAPC = - 1.46%). The trend of antidepressant use has been increasing steadily over the considered period. Public Health plays a key role in proposing solutions to improve the mental health of the population. Targeted interventions must be carried out to raise awareness among policy makers, clinicians and the population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.